Navigation Links
Viagra May Shield Heart From Blood Pressure Damage
Date:1/5/2009

Sildenafil appears to delay dangerous heart muscle expansion in mice

MONDAY, Jan. 5 (HealthDay News) -- Tests in mouse hearts show that sildenafil, the key ingredient in Viagra, may shield hearts from damage caused by high blood pressure, a new study suggests.

Investigators said that sildenafil appears to influence RGS2, a single protein essential in the reactions that initially protect the heart's blood-pumping function from spiraling into heart failure. The findings, published online Monday in The Journal of Clinical Investigation, suggest that sildenafil may prove useful in the treatment or prevention of heart damage due to chronic high blood pressure.

"Sildenafil clearly prolongs the protective effects of RGS2 in mouse hearts," senior investigator Dr. David Kass, a cardiologist and professor of medicine at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute in Baltimore, said in a Hopkins news release.

After a week of inducing high blood pressure in the mice, the team found that the hearts engineered to lack RGS2, or regulator of G-protein signaling 2, expanded in weight by 90 percent, and almost half of the experiment animals died of heart failure. In the mice with RGS2, the dangerous muscle expansion, known as hypertrophy, was delayed, growing by only 30 percent, the researchers found, and none of those mice died.

Later testing showed that treating hypertensive mice that had RGS2 with sildenafil showed enhanced buffering, less hypertrophy, and stronger heart muscle contraction and relaxation. In addition, these mice showed as much as 10 times lower stress-related enzyme activity compared to their untreated counterparts. The study also found that sildenafil had no effect in mice lacking RGS2.

The study involved more than a half-dozen experiments, all performed within the last three years, designed to zero in on RGS2's role in stalling hypertrophy.

"The evidence is piling up that unbridled Gq signaling is driving a central biological chain reaction in heart failure, and that by extending the protective effects of RGS2 or by developing a test for its presence, researchers can develop new therapies or improve existing ones, including ACE inhibitors and possibly sildenafil, for people with heart failure who will benefit most," Kass said.

Doctors currently use so-called ACE inhibitor and ARB inhibitor drugs to block Gq signaling. These drugs are the most common treatment for heart failure, which afflicts more than 5 million Americans each year, killing more than a quarter million of them, according to the study.

More information

For more on the symptoms of heart failure, go to American Heart Association.



-- HealthDay staff



SOURCE: Johns Hopkins University School of Medicine, news release, Jan. 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
2. For Patients Who Fail on Viagra, Levitra or Cialis
3. Viagra May Protect Hearts of Some Muscular Dystrophy Patients
4. TriMix-gel vs Viagra, Levitra, Cialis Data to Be Presented at AUA
5. AUDIO from Medialink and Pfizer: Viagras 10th Anniversary
6. An Important Message to Anyone Taking Viagra ... From The Women Who Love You ... and Zoller Labs
7. Blue Cross and Blue Shield of Florida Launches Cover Florida Plans for the Uninsured
8. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
9. Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits
10. Study Shows Exercise Shields Against Osteoporosis
11. Drug Shields Mice From Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Viagra May Shield Heart From Blood Pressure Damage
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is a ... mind and move the readers one step closer to God. “Psalms of Humidity” is ... his mistakes that have been made within his life are the very same things ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring ... their closets. “They Sang At Her Funeral” is the creation of published author, Annalise ... five children and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to ...
(Date:9/19/2017)... ... 19, 2017 , ... Only a few physicians were selected to receive the ... A. Clevens, MD, FACS . The founder and medical director of Clevens Face ... trained at Yale, Harvard and the University of Michigan. He has served patients throughout ...
(Date:9/19/2017)... ... , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. To ... $835 million in resolved debt for its clients. , Credit card debt, unpaid hospital ... of debt settled by the company. With more than a decade of combined service ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to Texas as a part of its national Swirl: ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology: